ReviewFrontiers in pharmacology2025
Non-hematopoietic roles of erythropoietin in inflammation and metabolic disorders.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high-fat diet-induced obese mice.FEBS open bio · 2026Article
- Article
- An inflammation-targeted lipid nanoparticle inhibiting ferroptosis for spinal cord injury repair.Materials today. Bio · 2026Article
- Peptide-Based Approaches for Pain Relief and Healing in Wounds.International journal of molecular sciences · 2026Review
- Erythropoietin alleviate obstructive renal fibrosis by regulating immunity and inflammation through miR-21-5p/SPRY1/ERK1/2/NF-κB pathway inhibition.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO), a glycoprotein hormone primarily produced by the kidneys, is essential for erythropoiesis. Beyond its well-established hematopoietic function, EPO has emerged as a regulator of metabolic inflammation. Obesity-induced chronic inflammation underlies insulin resistance, a key driver of metabolic disorders such as type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH). Recent evidence shows EPO exerts anti-inflammatory effects in insulin-sensitive tissues, thereby improving insulin sensitivity in the context of obesity. Although EPO is clinically approved for treating anemia in both neonates and adults, further evaluation is needed to establish its safety and tolerability when repurposed for metabolic indications across these populations. Nevertheless, to overcome the hematopoietic side effects of native EPO, researchers have developed non-hematopoietic analogs with selective tissue-protective actions. These analogs are currently under investigation and have shown therapeutic potential without erythropoietic side effects. This review summarizes the anti-inflammatory roles of EPO in obesity-related metabolic dysfunction, particularly in white adipose tissue (WAT) and the liver, and discusses the therapeutic potential of non-hematopoietic EPO analogs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.